the aid library

LIST OPTIONS

Filter

1890

Sort by:

Direction:

Download (572)

View PDF (1256)

Use of antibiotics for the treatment and control of cholera
recommended

Global Task Force for Cholera Control (2018) C1

Cholera is an acute diarrhoeal disease caused by the ingestion of food or water contaminated with the bacterium V. cholerae. It has a short incubation period of a few hours to 5 days. It is endemic in some countries, frequently showing seasonal variations in the number of reported cases. Cholera a... more

Download (284)

View PDF (1522)

Migration and health: key issues

World Health Organization WHO, Regional Office for Europe (2016) C_WHO

The most frequent health problems of newly arrived refugees and migrants include accidental injuries, hypothermia, burns, gastrointestinal illnesses, cardiovascular events, pregnancy- and delivery-related complications, diabetes and hypertension. Female refugees and migrants frequently face specific... more

Download (239)

View PDF (354)

No Time to Wait: Securing the future from drug-resistant infections

IACG Interagency Coordination Group on Antimicral Resistance (2019) C_WHO

UN, international agencies and experts released a groundbreaking report demanding immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis. If no action is taken - warns the UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance who release... more

Download (441)

View PDF (970)

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

World Health Organization WHO; Stop TB (2019) C_WHO

The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ... more

Download (405)

View PDF (783)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies

Alipanah N, Jarlsberg L et al. (2018) CC

We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB through February 3, 2018. We included randomized controlled trials (RCTs) as well as prospective and retro... more

Download (308)

View PDF (354)

HIV drug resistance report 2021

World Health Organization (WHO) (2021) C_WHO

The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO. Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo... more

Download (417)

View PDF (879)

WHO guidelines on use of medically important antimicrobials in food-producing animals

World Health Organization WHO (2017) C_WHO

These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... more

Download (91)

View PDF (597)

Curbing Antimicrobial Resistance in Food Animal Production

Johns Hopkins Center for a Livable Future (2016) C2

Antimicrobials are widely used in food animal production, and use is rapidly increasing. In an era of growing demand for animal products, there is an increasing trend towards the industrial production of food animals, especially in lower- and middle-income countries (LMICs). One hallmark of this me... more

Download (80)

View PDF (707)

Five keys to growing safer fruits and vegetables: promoting health by decreasing microbial contamination

World Health Organization WHO (2012) C_WHO

The importance of fruits and vegetables in nutritious and healthy diets is well recognized, and in recent years consumers have been encouraged to eat more of these products. For many countries, particularly developing countries, these products have become a valuable commodity. At the same time, food... more

Download (103)

View PDF (139)

Vietnam: National Action Plan on Combating Drug Resistance in the period from 2013 - 2020

Ministry of Health Vietnam (2013) C2

In Vietnam, most of the examination and treatment facilities are facing with of spread of bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at alarming level. The burden of drug resistance is increasing due to the increasing cost of treatment, prolonged t... more

Download (166)

View PDF (195)

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment,update

World Health Organization WHO (2022) C_WHO

These guidelines group all recommendations on TB care and support in one document and are complemented by an operational handbook. The guidelines are to be used primarily by national TB programmes, or their equivalents in Ministries of Health, stakeholders and technical organizations working on... more

Download (121)

View PDF (158)

International standards for the treatment of drug use disorders - Revised Edition Incorporating Results Of Field - Testing

World Health Organization WHO (2020) C_WHO

This document is based on currently available scientific evidence on treatment for drug use disorders and sets out a framework for the implementation of the Standards, in line with principles of public health care. The Standards identify major components and features of effective systems for the tre... more

Download (97)

View PDF (125)

Drug misuse: opoid detoxification

National Collaborating Centre for Mental Health NICE (2008) C1

The guideline on Drug misuse: opioid detoxification, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence-based recommendations for healthcare staff on how to work with people who misuse opioids to significantly improve their treatment a... more

Download (144)

View PDF (221)

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment
recommended

World Health Organization WHO (2022) C_WHO

The Quadripartite Organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Organisation for Animal Health (WOAH, founded as OIE), and the World Health Organization (WHO) – collaborate to drive the change and tra... more

Download (101)

View PDF (144)

WHO Drug Information - Volume 36, No. 4

World Health Organisation (WHO) (2023) C_WHO

Pharmaceutical News Evaluation of Saccharide Content of the WHO 2nd International Standard for Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP) by HPAECPAD Analysis Following Acid Hydrolysis Consultation Documents Lamivudine and tenofovir disoproxil fumarate tablets (lami... more

Download (143)

View PDF (218)

Chagas Disease: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Clinical Info HIV (2018) CC

Epidemiology Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or... more

Download (76)

View PDF (409)

Guidelines for the Prevention and Treatment of Opportunistic Infections

Clinical Info HIV gov. (2018) CC

Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or drink.1-4 The... more

Download (140)

View PDF (175)

Report 2022: pesticide residues in food: Joint FAO/WHO Meeting on Pesticide Residues

World Health Organisation (WHO) (2023) C_WHO

The annual Joint Meeting of the Food and Agriculture Organization of the United Nations (FAO) Panel of Experts on Pesticide Residues in Food and the Environment and the World Health Organization (WHO) Core Assessment Group on Pesticide Residues (JMPR) was held in Rome, Italy, from 13 to 22 September... more

Download (228)

View PDF (176)

Safety evaluation of certain contaminants in food: prepared by the ninety-first meeting of the Joint FAO/WHO Expert Committee on Food Additives (‎JECFA)‎

World Health Organisation (WHO) (2023) C_WHO

This volume contains monographs prepared at the ninety-first meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which met virtually online from 1 to 12 February 2021. The detailed monographs in this volume summarize data on specific contaminants in food. Individual monographs ... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Use of antibiotics for the treatment and control of cholera recommended

WHO consolidated guidelines on drug-resistant tuberculosis treatment recommended

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment recommended

Use of antibiotics for the treatment and control of cholera
recommended

WHO consolidated guidelines on drug-resistant tuberculosis treatment
recommended

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment
recommended